-
1.发明授权Monoclonal antibody which agglutinates E. coli having the CS4-CFA/I family protein 有权凝集具有CS4-CFA / I家族蛋白的大肠杆菌的单克隆抗体公开(公告)号：US07566540B2
公开(公告)日：2009-07-28
申请号：US10864803
申请日：2004-06-10
IPC分类号： G01N33/53 , G01N33/569
CPC分类号： C07K14/245 , A61K2039/505 , C07K16/1232 , C07K2317/34
摘要： A monoclonal antibody to a consensus peptide of the formula: VEKNITVTASVDPTIDLLQADGSALPSAVALTYSPA.(SEQ ID NO:1) The monoclonal antibody of the invention binds exclusively to the sequence SAVALTYS (SEQ ID NO:2) and has use as a diagnostic and for prophylaxis against illness arising from E. coli which produce the CS4-CFA/I family of proteins and for treatment of disease arising therefrom.
摘要翻译： 对于下列公式的共有肽的单克隆抗体：
VEKNITVTASVDPTIDLLQADGSALPSAVALTYSPA。 （SEQ ID NO：1） 本发明的单克隆抗体专门与SAVALTYS（SEQ ID NO：2）序列结合，并且可用作诊断和预防来自E. 大肠杆菌，其产生CS4-CFA / I家族蛋白质并用于治疗由此产生的疾病。 -
2.发明授权Nucleic acids encoding opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria 有权编码针对革兰氏阳性菌的脂磷壁酸特异性的调理单克隆和嵌合抗体的核酸公开(公告)号：US07777017B2
公开(公告)日：2010-08-17
申请号：US11724040
申请日：2007-03-13
申请人： Jeffrey R. Stinson , Richard F. Schuman , James Jacob Mond , Andrew Lees , Gerald Walter Fischer
发明人： Jeffrey R. Stinson , Richard F. Schuman , James Jacob Mond , Andrew Lees , Gerald Walter Fischer
CPC分类号： C07K16/1267 , A61K38/00 , A61K39/00 , A61K2039/505 , C07K14/195 , C07K16/1271 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/77 , C07K2319/00
摘要： The present invention encompasses monoclonal antibodies that bind to lipoteichoic acid (LTA) of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro. The invention also provides antibodies having human sequences (chimeric, humanized and human antibodies). The invention also sets forth the variable regions of three antibodies within the invention and presents the striking homology between them.
摘要翻译： 本发明包括与革兰氏阳性细菌的脂磷壁酸（LTA）结合的单克隆抗体。 抗体还与全细菌结合，增强体外吞噬细菌和杀死细菌。 本发明还提供具有人序列（嵌合，人源化和人抗体）的抗体。 本发明还阐述了本发明内三种抗体的可变区，并且它们之间具有引人注目的同源性。
-
3.发明授权Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria 失效革兰氏阳性细菌脂磷壁酸特异的口服单克隆和嵌合抗体公开(公告)号：US07250494B2
公开(公告)日：2007-07-31
申请号：US10323927
申请日：2002-12-20
CPC分类号： C07K16/1267 , A61K38/00 , A61K39/00 , A61K2039/505 , C07K14/195 , C07K16/1271 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/77 , C07K2319/00
摘要： The present invention encompasses monoclonal antibodies that bind to lipoteichoic acid (LTA) of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro. The invention also provides antibodies having human sequences (chimeric, humanized and human antibodies). The invention also sets forth the variable regions of three antibodies within the invention and presents the striking homology between them.
摘要翻译： 本发明包括与革兰氏阳性细菌的脂磷壁酸（LTA）结合的单克隆抗体。 抗体还与全细菌结合，增强体外吞噬细菌和杀死细菌。 本发明还提供具有人序列（嵌合，人源化和人抗体）的抗体。 本发明还阐述了本发明内三种抗体的可变区，并且它们之间具有引人注目的同源性。
-
4.发明授权Polynucleotides encoding humanized and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria 失效编码针对革兰氏阳性菌的脂磷壁酸特异性的人源化和嵌合抗体的多核苷酸公开(公告)号：US07884198B2
公开(公告)日：2011-02-08
申请号：US12317718
申请日：2008-12-23
CPC分类号： C07K14/195 , A61K38/00 , A61K39/00 , A61K2039/505 , C07K16/1267 , C07K16/1271 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/73 , C07K2317/77 , C07K2319/00
摘要： The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and/or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics.
摘要翻译： 本发明包括与革兰氏阳性细菌的脂磷壁酸结合的单克隆抗体和嵌合抗体。 抗体还结合全细菌，增强体外吞噬细菌和杀死细菌，增强体内致死感染的保护作用。 小鼠单克隆抗体已经人源化，所得到的嵌合抗体提供了以前未知的用于诊断，预防和/或治疗由具有脂磷壁酸的革兰氏阳性细菌引起的感染的方法。 本发明还包括由单克隆抗体限定的脂磷壁酸结合位点的肽模拟物。 该表位或表位肽模拟物鉴定可结合脂磷壁酸表位的其它抗体。 此外，表位或表位肽模拟物为生成疫苗或其他治疗剂提供了有价值的底物。
-
5.发明授权Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram posiive bacteria 失效口服和保护性单克隆抗体和嵌合抗体，特异于脂蛋白酸的细菌公开(公告)号：US08372958B2
公开(公告)日：2013-02-12
申请号：US10601171
申请日：2003-06-23
CPC分类号： C07K14/195 , A61K38/00 , A61K39/00 , A61K2039/505 , C07K16/1267 , C07K16/1271 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/73 , C07K2317/77 , C07K2319/00
摘要： The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and/or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics.
摘要翻译： 本发明包括与革兰氏阳性细菌的脂磷壁酸结合的单克隆抗体和嵌合抗体。 抗体还结合全细菌，增强体外吞噬细菌和杀死细菌，增强体内致死感染的保护作用。 小鼠单克隆抗体已经人源化，所得到的嵌合抗体提供了以前未知的用于诊断，预防和/或治疗由具有脂磷壁酸的革兰氏阳性细菌引起的感染的方法。 本发明还包括由单克隆抗体限定的脂磷壁酸结合位点的肽模拟物。 该表位或表位肽模拟物鉴定可结合脂磷壁酸表位的其它抗体。 此外，表位或表位肽模拟物为生成疫苗或其他治疗剂提供了有价值的底物。
-
6.发明授权Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria 有权针对革兰氏阳性菌的肽聚糖的多功能单克隆抗体公开(公告)号：US07169903B2
公开(公告)日：2007-01-30
申请号：US10323903
申请日：2002-12-20
申请人： Richard F. Schuman , John Fitzgerald Kokai-Kun , Simon J. Foster , Jeffrey R. Stinson , Gerald Walter Fischer
发明人： Richard F. Schuman , John Fitzgerald Kokai-Kun , Simon J. Foster , Jeffrey R. Stinson , Gerald Walter Fischer
IPC分类号： C12P21/08 , C07K16/00 , A61K39/085 , C07H21/04
CPC分类号： C07K16/1278 , A61K39/00 , A61K2039/505 , C07K16/1271 , C07K16/1275 , C07K2317/24 , C07K2317/77 , C07K2319/30
摘要： The present invention encompasses protective monoclonal antibodies that bind to peptidoglycan of Gram-positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and block nasal colonization by Gram-positive bacteria in vivo. The invention also provides human, humanized and chimeric antibodies. The invention also sets forth the heavy chain and light chain variable regions of an antibody within the invention.
摘要翻译： 本发明包括与革兰氏阳性菌的肽聚糖结合的保护性单克隆抗体。 抗体还结合全细菌，增强体外吞噬细菌和杀死细菌，并在体内阻断革兰氏阳性菌的鼻腔定植。 本发明还提供人，人源化和嵌合抗体。 本发明还阐述了本发明中抗体的重链和轻链可变区。
-
公开(公告)号：US5554542A
公开(公告)日：1996-09-10
申请号：US128451
申请日：1993-09-28
IPC分类号： C12N5/16 , A61K39/385 , C07K16/00 , C07K16/44 , C12N5/20 , C12N15/02 , C12N15/13 , C12P21/08 , G01N33/53 , G01N33/543 , G01N33/577 , G01N33/531
CPC分类号： G01N33/54353 , C07K16/44 , G01N33/5308 , Y10S436/815 , Y10T436/141111
摘要： Immunoassay for isothiazolones based on monoclonal antibodies that react with isothiazolones, particularly, 5-chloro-2-methyl-3-isothiazolone, hybridomas that produce such antibodies, especially ATCC HB 11435, a method of preparing an immunogenic conjugate of isothiazolones and a macromolecule carrier, a method of producing monoclonal antibodies reactive with isothiazolones, and compositions comprising monoclonal or polyclonal antibodies reactive with isothiazolones.
摘要翻译： 基于与异噻唑酮特别是5-氯-2-甲基-3-异噻唑酮反应的单克隆抗体的异噻唑酮的免疫测定，产生这种抗体的杂交瘤，特别是ATCC HB 11435，制备异噻唑啉酮和大分子载体的免疫原性缀合物的方法 ，产生与异噻唑酮反应的单克隆抗体的方法，以及包含与异噻唑酮反应的单克隆或多克隆抗体的组合物。
-
8.发明申请Humanized and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria 失效对革兰氏阳性菌的脂磷壁酸具有特异性的人源化和嵌合抗体公开(公告)号：US20100221822A1
公开(公告)日：2010-09-02
申请号：US12317718
申请日：2008-12-23
CPC分类号： C07K14/195 , A61K38/00 , A61K39/00 , A61K2039/505 , C07K16/1267 , C07K16/1271 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/73 , C07K2317/77 , C07K2319/00
摘要： The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and/or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics.
摘要翻译： 本发明包括与革兰氏阳性细菌的脂磷壁酸结合的单克隆抗体和嵌合抗体。 抗体还结合全细菌，增强体外吞噬细菌和杀死细菌，增强体内致死感染的保护作用。 小鼠单克隆抗体已经人源化，所得到的嵌合抗体提供了以前未知的用于诊断，预防和/或治疗由具有脂磷壁酸的革兰氏阳性细菌引起的感染的方法。 本发明还包括由单克隆抗体限定的脂磷壁酸结合位点的肽模拟物。 该表位或表位肽模拟物鉴定可结合脂磷壁酸表位的其它抗体。 此外，表位或表位肽模拟物为生成疫苗或其他治疗剂提供了有价值的底物。
-
9.发明授权Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria 失效对革兰氏阳性菌的脂磷壁酸特异的口服和保护性单克隆和嵌合抗体公开(公告)号：US06939543B2
公开(公告)日：2005-09-06
申请号：US09893615
申请日：2001-06-29
IPC分类号： C12N15/02 , A61K38/00 , A61K39/00 , A61K39/395 , A61P31/04 , C07K7/00 , C07K14/195 , C07K16/12 , C07K16/46 , C12P21/08 , C12Q1/18
CPC分类号： C07K14/195 , A61K38/00 , A61K39/00 , A61K2039/505 , C07K16/1267 , C07K16/1271 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/73 , C07K2317/77 , C07K2319/00
摘要： The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and/or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics.
摘要翻译： 本发明包括与革兰氏阳性细菌的脂磷壁酸结合的单克隆抗体和嵌合抗体。 抗体还结合全细菌，增强体外吞噬细菌和杀死细菌，增强体内致死感染的保护作用。 小鼠单克隆抗体已经人源化，所得到的嵌合抗体提供了以前未知的用于诊断，预防和/或治疗由具有脂磷壁酸的革兰氏阳性细菌引起的感染的方法。 本发明还包括由单克隆抗体限定的脂磷壁酸结合位点的肽模拟物。 该表位或表位肽模拟物鉴定可结合脂磷壁酸表位的其它抗体。 此外，表位或表位肽模拟物为生成疫苗或其他治疗剂提供了有价值的底物。
-
10.发明授权Humanized and chimeric antibodies specific for lipoteichoic acid of GRAM positive bacteria 失效对GRAM阳性细菌的脂磷壁酸特异的人源化和嵌合抗体公开(公告)号：US07511122B2
公开(公告)日：2009-03-31
申请号：US11193440
申请日：2005-08-01
IPC分类号： C12P21/08 , C07K16/00 , A61K39/395 , G01N33/574 , C12P21/04 , C07H21/04
CPC分类号： C07K14/195 , A61K38/00 , A61K39/00 , A61K2039/505 , C07K16/1267 , C07K16/1271 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/73 , C07K2317/77 , C07K2319/00
摘要： The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. The mouse monoclonal antibody has been humanized and the resulting chimeric antibody provides a previously unknown means to diagnose, prevent and/or treat infections caused by gram positive bacteria bearing lipoteichoic acid. This invention also encompasses a peptide mimic of the lipoteichoic acid epitope binding site defined by the monoclonal antibody. This epitope or epitope peptide mimic identifies other antibodies that may bind to the lipoteichoic acid epitope. Moreover, the epitope or epitope peptide mimic provides a valuable substrate for the generation of vaccines or other therapeutics.
摘要翻译： 本发明包括与革兰氏阳性细菌的脂磷壁酸结合的单克隆抗体和嵌合抗体。 抗体还结合全细菌，增强体外吞噬细菌和杀死细菌，增强体内致死感染的保护作用。 小鼠单克隆抗体已经人源化，所得到的嵌合抗体提供了以前未知的用于诊断，预防和/或治疗由具有脂磷壁酸的革兰氏阳性细菌引起的感染的方法。 本发明还包括由单克隆抗体限定的脂磷壁酸结合位点的肽模拟物。 该表位或表位肽模拟物鉴定可结合脂磷壁酸表位的其它抗体。 此外，表位或表位肽模拟物为生成疫苗或其他治疗剂提供了有价值的底物。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.025 秒)
